Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

KTRADelisted Stock  USD 6.30  0.14  2.17%   
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. , announced that the two parties have entered into a strategic collaboration regarding limertinib, a third-generation epidermal growth factor receptor EG

Read at finance.yahoo.com
Yahoo News
  

Kintara Therapeutics Fundamental Analysis

We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Kintara Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Kintara Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.

Peers

Kintara Therapeutics Related Equities

ONCYOncolytics Biotech   2.47   
0%
14.0%
SLRXSalarius Pharmaceuticals   2.08   
0%
12.0%
SCPHScpharmaceuticals   1.57   
0%
9.0%
MCRBSeres Therapeutics   1.14   
0%
6.0%
DYAIDyadic International   0.62   
0%
3.0%
LUMOLumos Pharma   0.23   
0%
1.0%
LSTALisata Therapeutics   0.00   
0%
0%
MISTMilestone Pharmaceuticals   0.56   
3.0%
0%
TOVXTheriva Biologics   0.84   
5.0%
0%
VCNXVaccinex   1.08   
6.0%
0%
DMACDiaMedica Therapeutics   1.30   
7.0%
0%
BOLTBolt Biotherapeutics   2.83   
16.0%
0%
GOVXGeoVax Labs   3.40   
20.0%
0%
SABSSAB Biotherapeutics   4.17   
24.0%
0%
CLRBCellectar Biosciences   9.23   
54.0%
0%
FBRXForte Biosciences   16.80   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges